MSMegha Singh

Megha Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Megha Singh has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pregnancy complications and risk of cardiometabolic-renal conditions in 1.4 million women in England: longitudinal study

    by Steven Wambua, Megha Singh, Mohamed Rishard, Nadia Sarween, Pushpa Singh, Christopher Yau, Richard D Riley, Nicola J Adderley, Kym I E Snell, Francesca L Crowe, et al.

    Objective: To investigate the association between pregnancy complications and cardiometabolic-renal conditions (ie, cardiovascular disease, type 2 diabetes mellitus, hypertension, and chronic kidney disease) in the subsequent years after pregnancy. Design: Longitudinal study. Setting: Clinical Practice Research Datalink (CPRD) Aurum primary care database pregnancy register, UK, 1 January 2000 to 31 December 2022. Participants: 1 432 795 women, aged 15-49 years, who had been pregnant, with or without pregnancy complications, and registered with a general practitioner between 1 January 2000 and 31 December 2022. Main outcome measures: First recorded diagnosis of each of the four conditions: cardiovascular disease (ischaemic heart disease or cerebrovascular disease, including stroke and transient ischaemic attack), type 2 diabetes mellitus, hypertension, and chronic kidney disease (stages 3-5). Results: 1 422 287 participants were included in the cardiovascular disease outcome analysis, 1 389 460 in the hypertension, 1 411 883 in the type 2 diabetes mellitus, and 1 430 965 in the chronic kidney disease cohorts. Median follow-up was 4.1-4.3 years across the four cohorts (interquartile range approximately 1.5-9.8). Of 72 associations examined, 51 were significant after correction for multiple testing. Well established associations were found. Gestational hypertension and pre-eclampsia more than tripled the rate of hypertension and approximately doubled the rate of chronic kidney disease, with smaller increases for cardiovascular disease and type 2 diabetes mellitus. Gestational diabetes mellitus was associated with a sevenfold higher rate of type 2 diabetes mellitus and increased rates for hypertension and cardiovascular disease, but not for chronic kidney disease. Less well established associations were also found. Postnatal depression increased the rate of all four outcomes by 35-56% for the latest pregnancy (hypertension hazard ratio 1.36, 95% confidence interval (CI) 1.33 to 1.40; type 2 diabetes mellitus hazard ratio 1.41, 1.36 to 1.46; cardiovascular disease hazard ratio 1.56, 1.50 to 1.62; and chronic kidney disease hazard ratio 1.35, 1.25 to 1.45). Miscarriage, stillbirth, placental abruption, and preterm birth in the latest or in a previous pregnancy were associated with modestly higher rates of one or more outcomes (eg, stillbirth in the latest pregnancy: type 2 diabetes mellitus hazard ratio 1.67, 95% CI 1.33 to 2.08 and chronic kidney disease hazard ratio 1.79, 1.19-2.70; placental abruption in the latest pregnancy: chronic kidney disease hazard ratio 1.67, 1.06 to 2.62). Small-for-gestational-age birth was associated with higher rates of hypertension and cardiovascular disease, and large-for-gestational-age birth with higher rates for type 2 diabetes mellitus, including without gestational diabetes mellitus. Conclusions: Several pregnancy complications, including those occurring in previous pregnancies, were associated with an increased risk of cardiometabolic-renal conditions in the subsequent years after pregnancy. These findings support obtaining a full reproductive history and using the postpartum period as an opportune time for risk assessment and preventive cardioprotective strategies in women with a history of adverse pregnancy outcomes.

  • Open Access

    Autoimmune diseases and risk of adverse pregnancy outcomes: a population-based cohort study of five million pregnancies in the UK

    by Megha Singh, Anuradhaa Subramanian, Steven Wambua, Neil Cockburn, Stephanie J Hanley, Siang Ing Lee, Arturo Gonzalez-Izquierdo, Mairead Black, John A Reynolds, Francesca L Crowe, et al.

    Background: With an increasing trend in the prevalence of maternal autoimmune diseases in pregnancy, there is need for evidence on the association between autoimmune diseases and pregnancy outcomes. Methods: This population-based cohort study used data on pregnancies from primary care practices that contributed to the UK Clinical Practice Research Datalink (CPRD) database (Gold and Aurum) between 2000 and 2022, linked to Hospital Episode Statistics (HES). Modified Poisson regression with robust standard errors estimated adjusted relative risks (aRR) and 95% confidence intervals (95% CI) assessing the association between 17 autoimmune diseases and 12 pregnancy outcomes, selected following literature review and expert consultation. Models were adjusted for demographic and comorbidity variables. Findings were evaluated using the Benjamini–Yekutieli procedure to control for multiple testing across autoimmune disease–outcome associations. Results: A total of 5,239,383 pregnancies from the CPRD pregnancy register and 2,485,366 births recorded in HES maternity data met the eligibility criteria. Women with autoimmune diseases had an increased risk across all pregnancy outcomes examined. Among antenatal outcomes, markedly elevated risks were observed for hyperemesis gravidarum in Addison’s disease (aRR 3.72, 95% CI 2.48–5.59), miscarriage in Sjögren’s syndrome (1.66, 1.02–2.70), gestational hypertension in type 1 diabetes mellitus (T1DM; 2.95, 2.77–3.15), pre-eclampsia/eclampsia in T1DM (3.56, 3.32–3.82), and gestational diabetes mellitus in Graves’ disease (1.37, 1.21–1.54). For obstetric outcomes, increased risks were observed for caesarean birth in inflammatory bowel disease (IBD; 1.27, 1.22–1.31), small for gestational age in systemic lupus erythematosus (SLE; 2.45, 1.65–3.62), preterm birth in rheumatoid arthritis (1.53, 1.33–1.76), and stillbirth in SLE (1.82, 1.12–1.84). Perinatal mental health outcomes were more common across several autoimmune diseases, with particularly high risks in myasthenia gravis (anxiety 3.05, 1.89–4.92; depression 1.77, 1.37–2.28), SLE (anxiety 2.11, 1.67–2.67; depression 1.36, 1.22–1.53), and multiple sclerosis (anxiety 1.76, 1.38–2.23; depression 1.94, 1.77–2.12). Inverse associations were observed for hyperemesis gravidarum in systemic sclerosis, SLE, and myasthenia gravis, and for hypertensive disorders of pregnancy in multiple sclerosis. After Benjamini–Yekutieli correction for multiple testing, the number of statistically significant associations was reduced, with a core set of robust associations persisting across selected autoimmune diseases particularly, T1DM, SLE, Graves’ disease, IBD and key pregnancy outcomes. Conclusions: Autoimmune diseases were associated with increased risks across a wide range of adverse pregnancy outcomes, with marked heterogeneity between individual conditions. This study provides adjusted relative risks across multiple domains of pregnancy outcomes including antenatal (e.g. miscarriage, hyperemesis gravidarum, gestational hypertension, pre-eclampsia, gestational diabetes), obstetric (e.g. preterm birth, caesarean birth, small for gestational age, stillbirth), and perinatal mental health outcomes (anxiety and depression), for both common and less frequently studied autoimmune diseases. The findings highlight the importance of disease-specific evaluation of pregnancy risks.


  • Open Access

    The association of pregnancy complications/risk factors with the development of cancer in women: an umbrella review

    by Jemma Healey, Megha Singh, Clare Richards, Rachel Plachcinski, Ngawai Moss, Leila Ghalichi, Siang Ing Lee, Stephanie Hanley, Zoe Vowles, Francesca L. Crowe, et al.

    Background: Among women in the UK, over 186,000 new cancer diagnoses and around 78,000 cancer deaths occurred annually from 2017 to 2019. Evidence suggests that pregnancy complications are linked to mortality and morbidity risks in later life. This umbrella review aims to assess the association between pregnancy complications and cancer risk. It forms part of a series of studies exploring associations between pregnancy complications and long-term health conditions. Methods: MEDLINE, Embase, and Cochrane databases were searched from inception to April 2024. Key search terms encompassed ‘cancer’ and ‘pregnancy complications’ or ‘pregnancy risk factors’. Screening data extraction and quality appraisal (AMSTAR 2) were completed by two independent reviewers. Data were synthesised narratively and quantitatively. Relative risks (RR)/odds ratio (OR)/hazard ratios (HR) with 95% confidence intervals were reported. Results: Of the 25 reviews assessed for methodological quality, 2 were rated high, 12 moderate, 9 low, and 2 critically low. After excluding 10 overlapping reviews and 2 critically low reviews, 13 reviews included reviews consisted of 170 primary studies. Associations between 7 pregnancy complications and 17 cancers are reported. Women with molar pregnancy had four-fold higher risk of developing gestational trophoblastic neoplasia [OR 4.72 (1.81–12.32)]. Miscarriage was associated with thyroid cancer [OR 1.29 (95% CI 1.15–1.44)], but not with breast or ovarian cancer. Pre-eclampsia was associated with a reduced risk of breast cancer [RR 0.89 (0.83–0.95)] and an almost twofold higher risk of ovarian cancer [RR 1.82 (1.16–2.85)]. Gestational diabetes mellitus was associated with a higher risk of thyroid cancer [RR 1.28 (1.16–1.42)], stomach cancer [RR 1.43 (1.02–2.00)], liver cancer [RR 1.27 (1.03–1.55)], and blood cancer [RR 1.48 (1.04–2.09)] but was not associated with other cancers studied. Preterm birth showed a very small association with breast cancer risk (OR 1.03, 95% CI 1.00–1.07). There was no significant association between caesarean section and cervical cancer or multiple births and breast cancer. Conclusions: Some pregnancy complications were associated with selected cancer outcomes, although the evidence was heterogeneous and limited by potential bias, confounding, and inconsistent review quality.

  • Open Access

    ‘It Was a Bit of a Now or Never Situation’: Experiences of Preconception Care and Support for Women With Multiple Long‐Term Health Conditions

    by Stephanie J. Hanley, Sharon McCann, Siang Ing Lee, Danielle Schoenaker, Megha Singh, Ngawai Moss, Nishshanka Mudiyanselage Chamendi Lakshrieni Nishshanka, Zoe Vowles, Rachel Plachcinski, Krishnarajah Nirantharakumar, et al.

    Introduction: One in five women enters pregnancy with multiple long‐term health conditions, which is associated with increased risks of adverse maternal and child outcomes. There is a lack of research exploring individuals' experiences of preconception care for these women, which is also reflected in existing guidelines that predominantly focus on single health conditions. This study aimed to explore experiences of preconception care and support among women with multiple long‐term health conditions and health professionals. Methods: This is a secondary analysis of qualitative data collected by the MuM‐PreDiCT consortium. The primary study involved semi‐structured interviews between March 2022 and May 2023 with pregnant (> 28 weeks) and postnatal (< 2 years) women with multiple long‐term physical and/or mental health conditions in the United Kingdom, and healthcare professionals involved in their care. Data captured within the preconception coding reports were analysed thematically. Results: Fifty‐seven women and 51 healthcare professionals were interviewed. Six themes were identified from the thematic analysis. Women and professionals described the importance of tailored preconception care and support, incorporating condition‐focused counselling (sub‐theme 1) and medication planning (sub‐theme 2). Sensitive and realistic care and support were considered essential, but women had mixed experiences of involvement and empathy from different professionals. The significance of optimising antenatal care by making every preconception contact count was emphasised by both women and professionals, who valued early referrals, specialist input and integration of services. Although professionals viewed the preconception period as an opportunity to empower women, many women felt they had to self‐advocate and seek information due to gaps in professional awareness, knowledge and education. Professionals reported differing views on who, within the care team, should take responsibility for care delivery. Some believed that women should play an active role in managing their health, including initiating conversations around pregnancy intentions. The delivery of preconception care was complicated by a range of challenges, including a lack of service integration, availability, time and funding. Conclusion: Women with long‐term health conditions can experience substantial gaps in preconception care, characterised by inconsistent guidance and limited access to tailored, reliable support, which frequently leads to feelings of isolation and the need to seek additional information when preparing for pregnancy. These results will inform the co‐development of a care bundle for affected women. Patient or Public Contribution: Our Patient and Public Involvement group was involved in the design of the study and the analysis and interpretation of the data, and two public study investigators are part of the author group.


  • Open Access

    Maternity care bundle for UK women with multiple long-term health conditions: coproduction workshops

    by Stephanie Hanley, Sharon McCann, Megha Singh, Zoe Vowles, Siang Ing Lee, Rachel Plachcinski, Krishnarajah Nirantharakumar, Mairead Black, Louise Locock, Beck Taylor

    Objective: The objective of this study is to co-produce a care bundle for women with multiple long-term health conditions (MLTC) that could be pilot tested and implemented in UK maternity services. Design: Online co-production workshops each attended by 20–30 key interest holders. Setting: United Kingdom, October 2023-February 2024. Population: Women with experience of pregnancy with MLTC, healthcare professionals and other interest holders involved in commissioning, planning and delivering care for pregnant women with MLTC. Methods: This study followed a three-step process: (1) a consolidated list of key components of care for pregnant women with MLTC was created through secondary analysis of prior collected qualitative data; (2) the list of care components was explored during four co-production workshops; and (3) findings from (1) and (2) were synthesised to develop a maternity care bundle of 4–5 key care components for pregnant women with MLTC. Main outcome measures: A maternity care bundle of five key care components for pregnant women with MLTC. Results: A list of 25 care components was refined to develop a proposed care bundle of five components. These were provisions of early and reliable medication advice and decision support; creation of a ‘goals of care summary’ accessible to women and the care team; provision of continuity of midwifery care throughout pregnancy and postnatal care; provision of a named care coordinator; and a formal postnatal handover of care from the multidisciplinary care team to the General Practitioner (GP) and secondary care team involving the woman. Conclusions: This study coproduced an evidence-based care bundle for pregnant women with MLTC to enhance communication and ensure individualised care and support. Further collaborative work with women and professionals is required to refine, implement and evaluate its impact on outcomes.


  • Open Access

    Pregnancy complications and autoimmune diseases in women: systematic review and meta-analysis

    by Megha Singh, Fathima Fazla Ahamed Fayaz, Jingya Wang, Steven Wambua, Anuradha Subramanian, John A. Reynolds, Krishnarajah Nirantharakumar, Francesca Crowe, on behalf of MuM-PreDiCT

    Background: Pregnancy complications might lead to the development of autoimmune diseases in women. This review aims to summarise studies evaluating the association between pregnancy complications and the development of autoimmune diseases in women. Methods: Medline, CINAHL, and Cochrane databases were searched up to January 2024. Nineteen pregnancy complications and 15 autoimmune conditions were included. Title, abstract, full-text screening, data extraction, and quality assessment were performed by two reviewers independently. Data were synthesised using narrative and quantitative methods. Results were presented using odds ratios (OR), relative risks (RR), incidence rate ratios (IRR), and 95% confidence intervals (CI). Results: Thirty studies were included. One study reported composite exposure to pregnancy complications had a risk of any autoimmune disease RR 3.20 (2.90–3.51) compared to women without pregnancy complications. Women with hyperemesis gravidarum had a higher risk of developing coeliac disease (n = 1) IRR 1.98 (1.27–2.94), Crohn’s disease (n = 1) IRR 1.61 (1.25–2.04), psoriasis (n = 1) IRR 1.33 (1.01–1.71), and rheumatoid arthritis (n = 2) IRR 1.35 (1.09–1.64). Miscarriage associated with subsequent diagnosis of Sjogren syndrome (n = 2) IRR 1.33 (1.06–2.81) and rheumatoid arthritis (n = 4) OR 1.11 (1.04–1.20). Gestational hypertension/preeclampsia was linked with the development of systemic sclerosis (n = 2) IRR 2.60 (1.10–4.60) and T1DM (n = 2) IRR 2.37 (2.09–2.68). Stillbirth associated with composite autoimmune conditions (n = 2) RR 5.82 (95% CI 4.87–6.81) and aIRR 1.25 (1.12–1.40). Postpartum psychosis was associated with autoimmune thyroid disease (n = 1) aIRR2.26 (1.61–2.90). Conclusions: Women with pregnancy complications subsequently had a higher risk of being diagnosed with autoimmune conditions. Whether this is due to pre-existing undiagnosed health conditions or being causally linked to pregnancy complications is not known.


  • Top Cited Papers
    Open Access

    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review

    by Megha Singh, Steven Wambua, Siang Ing Lee, Kelvin Okoth, Zhaonan Wang, Fathima Fazla Ahamed Fayaz, Kelly-Ann Eastwood, Catherine Nelson-Piercy, John A. Reynolds, Krishnarajah Nirantharakumar, et al.

    Background: There is a high prevalence of autoimmune conditions in women specially in the reproductive years; thus, the association with adverse pregnancy outcomes has been widely studied. However, few autoimmune conditions/adverse outcomes have been studied more than others, and this umbrella review aims to consolidate existing knowledge in this area with the aim to provide new knowledge and also identify gaps in this research area. Methods: Medline, Embase, and Cochrane databases were searched from inception to December 2023. Screening, data extraction, and quality appraisal (AMSTAR 2) were done by two independent reviewers. Data were synthesised narratively and quantitatively. Relative risks (RR)/odds ratio (OR) with 95% confidence intervals were reported. Results: Thirty-two reviews were included consisting of 709 primary studies. The review reported the association between 12 autoimmune conditions and 16 adverse pregnancy outcomes. Higher risk of miscarriage is reported in women with Sjögren’s syndrome RR 8.85 (95% CI 3.10–25.26) and systemic lupus erythematosus (SLE) OR 4.90 (3.10–7.69). Pre-eclampsia was reported higher in women with type 1 diabetes mellitus (T1DM) OR 4.19 (3.08–5.71) and SLE OR 3.20 (2.54–4.20). Women reported higher risk of diabetes during pregnancy with inflammatory bowel disease (IBD) OR 2.96 (1.47–5.98). There was an increased risk of intrauterine growth restriction in women with systemic sclerosis OR 3.20 (2.21–4.53) and coeliac disease OR 1.71 (1.36–2.14). Preterm birth was associated with T1DM OR 4.36 (3.72–5.12) and SLE OR 2.79 (2.07–3.77). Low birth weight babies were reported in women with women with SLE or systemic sclerosis OR 5.95 (4.54–7.80) and OR 3.80 (2.16–6.56), respectively. There was a higher risk of stillbirth in women with T1DM OR 3.97 (3.44–4.58), IBD OR 1.57 (1.03–2.38), and coeliac disease OR 1.57 (1.17–2.10). T1DM in women was associated with 32% lower odds of small for gestational age baby OR 0.68 (0.56–0.83). Conclusions: Pregnant women with autoimmune conditions are at a greater risk of developing adverse pregnancy outcomes. Further research is required to develop better preconception to postnatal care for women with autoimmune conditions.


  • Open Access

    Detection and evaluation of signals associated with exposure to individual and combination of medications in pregnancy: a signal detection study protocol

    by Anuradhaa Subramanian, Siang Ing Lee, Sudasing Pathirannehelage Buddhika Hemali Sudasinghe, Steven Wambua, Katherine Phillips, Megha Singh, Amaya Azcoaga-Lorenzo, Neil Cockburn, Jingya Wang, Adeniyi Fagbamigbe, et al.

    Introduction Considering the high prevalence of polypharmacy in pregnant women and the knowledge gap in the risk–benefit safety profile of their often-complex treatment plan, more research is needed to optimise prescribing. In this study, we aim to detect adverse and protective effect signals of exposure to individual and pairwise combinations of medications during pregnancy. Methods and analysis Using a range of real-world data sources from the UK, we aim to conduct a pharmacovigilance study to assess the safety of medications prescribed during the preconception period (3 months prior to conception) and first trimester of pregnancy. Women aged between 15 and 49 years with a record of pregnancy within the Clinical Practice Research Datalink (CPRD) Pregnancy Register, the Welsh Secure Anonymised Information Linkage (SAIL), the Scottish Morbidity Record (SMR) data sets and the Northern Ireland Maternity System (NIMATS) will be included. A series of case control studies will be conducted to estimate measures of disproportionality, detecting signals of association between a range of pregnancy outcomes and exposure to individual and combinations of medications. A multidisciplinary expert team will be invited to a signal detection workshop. By employing a structured framework, signals will be transparently assessed by each member of the team using a questionnaire appraising the signals on aspects of temporality, selection, time and measurement-related biases and confounding by underlying disease or comedications. Through group discussion, the expert team will reach consensus on each of the medication exposure–outcome signal, thereby excluding spurious signals, leaving signals suggestive of causal associations for further evaluation. Ethics and dissemination Ethical approval has been obtained from the Independent Scientific Advisory Committee, SAIL Information Governance Review Panel, University of St. Andrews Teaching and Research Ethics Committee and Office for Research Ethics Committees Northern Ireland (ORECNI) for access and use of CPRD, SAIL, SMR and NIMATS data, respectively.

  • Open Access

    Public and patient involvement (PPI) in systematic reviews: challenges in Sri Lankan setting and recommendations for the potential way forward

    by Fazla Fayaz, Siang Ing Lee, Krishnarajah Nirantharakumar, Megha Sing, Buddhika Mahesh

    Introduction: Public and patient involvement (PPI) in systematic reviews is an area of growing interest due to the importance of ensuring that research is relevant, appropriate and acceptable to the people it seeks to benefit.Objectives: To provide an overview of the rationale and methods for involving the public in systematic reviews, as well as identify common and specific challenges associated with it while carrying it out in low-resource setting in a country like Sri LankaMethods: The report begins with an introduction to PPI and its importance in health research, followed by a description of PPI involvement in each step of a systematic review. The report then explores the resources available to guide researchers on how to incorporate PPI into systematic reviews and identifies the barriers that exist to effective PPI.Conclusions & Recommendations: The report concludes by highlighting the importance of PPI in systematic reviews and the need for more work to promote greater engagement and involvement of patients and the public in research in Sri Lankan context.